BioSpace News Archive

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it will host an investor conference call and webcast on the INOpulse® inhaled nitric oxide system (iNO) for the treatment of COVID-19 at 1:00 PM EDT.

Phase 2 clinical data in NASH accepted for late-breaker oral presentation; preclinical data accepted for poster presentation

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety.

Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians and their patients who are battling to treat wounds amid disruption to many existing U.S. facilities for wound care due to COVID-19. Aroa Vice President Commercial, Brad Adams says the company has opened an additional pathway for its clinicians and patients to maintain access to Endoform®, an extracellular matrix technology that is proven to

Covalon Announces New Breakthrough Antimicrobial Technology Formulated to Kill The COVID-19 Virus

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today released a new video on its website showing the efficacy of its lead drug candidate Metablok in reducing neutrophil recruitment in a mouse model of lung inflammation. The new video can be viewed at the Arch Biopartners website here (click to view) .

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it had produced five COVID-19 vaccine candidates for testing in its preclinical models.

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it has entered into a credit facility with Bridge Bank, a division of Western Alliance Bank, effective March 30, 2020.

Zucara Therapeutics Inc. announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund.

BioSig Technologies, Inc. announced that it appointed Jerome Zeldis, M.D., Ph.D as Executive Chair of ViralClear Pharmaceuticals, Inc., a new division within its majority-owned subsidiary NeuroClear Technologies, Inc., which recently acquired the rights to develop a novel pharmaceutical to treat Coronavirus Disease 2019.